View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 26, 2022

Harbour BioMed concludes first patient dosing in Phase I antibody trial

The HBM7008 antibody has crosslinking dependent specificity on tumours and potent immune modulation activity.

Harbour BioMed has concluded the first participant dosing in Phase I clinical trial of HBM7008, a bispecific antibody that acts on Tumor Associated Antigen B7H4x4-1BB, in Australia.

In this study, the company will evaluate HBM7008’s tolerability, safety, pharmacokinetics, pharmacodynamics, and initial anti-tumour activity in solid tumour patients.

Developed from the company’s HBICE platform, using the advantages of HBM HCAb and H2L2 platforms, HBM7008 targets B7H4, mediated crosslinking T cell activation through 4-1BB.

B7H4 is overexpressed on various solid tumours, including ovarian, breast, endometrial, and non-small cell lung cancers.

HBM7008 has crosslinking dependent specificity on tumours and potent immune modulation activity and demonstrated safety profile in pre-clinical study.

Harbour BioMed said in a statement: “As the first-in-class bispecific antibody targeting B7H4 and 4-1BB, HBM7008 is expected to lead the development of next-generation immunotherapeutic.

“Following its global innovation and development strategy, Harbour BioMed will advance the global clinical development project of HBM7008 at full speed.”

Displaying high potency in the T cell co-stimulation and tumour growth inhibition, HBM7008 may also translate to better safety due to its TAA-mediated crosslinking T cell activation dependency.

Due to its unique specificity on tumours and immune modulation activity, the antibody is said to be a promising therapeutic in PD-L1 negative or PD-1/PD-L1 resistant patients.

Furthermore, it has the potential to avoid 4-1BB liver toxicity risk observed in other products.

Last month, Harbour BioMed announced an international out-license agreement with AstraZeneca for CLDN18.2xCD3 bispecific antibody HBM7022.

In May last year, Harbour BioMed started dosing patients with HBM4003 in the second Phase I part of a Phase Ib/IIa trial for solid tumours.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena